Cancer Research Cancer Epigenetics  Telomeres
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Ferrario, A.
Right arrow Articles by Gomer, C. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Ferrario, A.
Right arrow Articles by Gomer, C. J.
[Cancer Research 65, 9473-9478, October 15, 2005]
© 2005 American Association for Cancer Research


Experimental Therapeutics, Molecular Targets, and Chemical Biology

Celecoxib and NS-398 Enhance Photodynamic Therapy by Increasing In vitro Apoptosis and Decreasing In vivo Inflammatory and Angiogenic Factors

Angela Ferrario1, Anita M. Fisher1, Natalie Rucker1 and Charles J. Gomer1,2

1 The Saban Research Institute, Children's Hospital Los Angeles and 2 Departments of Pediatrics and Radiation Oncology, Keck School of Medicine, University of Southern California, Los Angeles, California

Requests for reprints: Charles J. Gomer, Children's Hospital Los Angeles, Mail Stop 67, 4650 Sunset Boulevard, Los Angeles, CA 90027. Phone: 323-669-2335; Fax: 323-669-0742; E-mail: cgomer{at}chla.usc.edu.

Photodynamic therapy (PDT) elicits both apoptotic and necrotic responses within treated tumors and produces microvascular injury leading to inflammation and hypoxia. PDT also induces expression of angiogenic and survival molecules including vascular endothelial growth factor, cyclooxygenase-2 (COX-2), and matrix metalloproteinases. Adjunctive administration of inhibitors to these molecules improves PDT responsiveness. In the current study, we examined how the combination of PDT and COX-2 inhibitors improve treatment responsiveness. Photofrin-mediated PDT combined with either celecoxib or NS-398 increased cytotoxicity and apoptosis in mouse BA mammary carcinoma cells. Immunoblot analysis of protein extracts from PDT-treated cells also showed poly(ADP-ribose) polymerase cleavage and Bcl-2 degradation, which were further enhanced following combined therapy. Tumor-bearing mice treated with PDT and either celecoxib or NS-398 exhibited significant improvement in long-term tumor-free survival when compared with PDT or COX-2 inhibitor treatments alone. The combined procedures did not increase in vivo tumor-associated apoptosis. Administration of celecoxib or NS-398 attenuated tissue levels of prostaglandin E2 and vascular endothelial growth factor induced by PDT in treated tumors and also decreased the expression of proinflammatory mediators interleukin-1ß and tumor necrosis factor-{alpha}. Increased tumor levels of the antiinflammatory cytokine, interleukin 10, were also observed following combined treatment. This study documents for the first time that adjunctive use of celecoxib enhances PDT-mediated tumoricidal action in an in vivo tumor model. Our results also show that administration of COX-2 inhibitors enhance in vitro photosensitization by increasing apoptosis and improve in vivo PDT responsiveness by decreasing expression of angiogenic and inflammatory molecules.




This article has been cited by other articles:


Home page
Am. J. Pathol.Home page
S. Tsunoda, H. Sakurai, Y. Saito, Y. Ueno, K. Koizumi, and I. Saiki
Massive T-Lymphocyte Infiltration into the Host Stroma Is Essential for Fibroblast Growth Factor-2-Promoted Growth and Metastasis of Mammary Tumors via Neovascular Stability
Am. J. Pathol., February 1, 2009; 174(2): 671 - 683.
[Abstract] [Full Text] [PDF]


Home page
ChestHome page
Y. Nakagishi, Y. Morimoto, M. Fujita, N. Morimoto, Y. Ozeki, T. Maehara, and M. Kikuchi
Photodynamic Therapy for Airway Stenosis in Rabbit Models
Chest, January 1, 2008; 133(1): 123 - 130.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
A. Ferrario, N. Rucker, S. Wong, M. Luna, and C. J. Gomer
Survivin, a Member of the Inhibitor of Apoptosis Family, Is Induced by Photodynamic Therapy and Is a Target for Improving Treatment Response
Cancer Res., May 15, 2007; 67(10): 4989 - 4995.
[Abstract] [Full Text] [PDF]


Home page
The OncologistHome page
M. Triesscheijn, P. Baas, J. H. M. Schellens, and F. A. Stewart
Photodynamic Therapy in Oncology
Oncologist, October 1, 2006; 11(9): 1034 - 1044.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Solban, S. K. Pal, S. K. Alok, C. K. Sung, and T. Hasan
Mechanistic Investigation and Implications of Photodynamic Therapy Induction of Vascular Endothelial Growth Factor in Prostate Cancer
Cancer Res., June 1, 2006; 66(11): 5633 - 5640.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 2005 by the American Association for Cancer Research.